Skip to content
Biotechnology

Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance

ZeptoMetrix 2 mins read

TRONDHEIM, NORWAY / ACCESSWIRE / January 17, 2024 / Chiron AS, a leading producer of chemical reference materials headquartered in Trondheim, Norway, is pleased to announce the establishment of a state-of-the-art research centre dedicated to the enhanced surveillance of environmental pollutants.



This ground-breaking development, supported by an estimated 40 million NOK investment, reaffirms Chiron's commitment to advancing the field of environmental analysis.

The newly inaugurated research facility, which offers a 360-degree view of the Trondheim fjord, is equipped to address the most challenging pollutants of today, including microplastics and PFAS (commonly known as ‘forever chemicals'), and is poised to contribute significant research into environmental surveillance.

This strategic relocation follows Chiron's acquisition by Antylia Scientific in July 2023 and its successful incorporation into the ZeptoMetrix® Operating Division. The move to the new 1750 m2 premises aligns Chiron with Spex®, NSI Laboratories and High Purity Standards in strengthening the ZeptoMetrix Reference Material and Proficiency Testing portfolio.

"We are excited to embark on this journey of heightened environmental surveillance," Jon Eigill Johansen, Founder of Chiron AS, commented. "The establishment of our research centre highlights our commitment to scientific excellence. Through cutting-edge research and collaboration, we aim to support our mission to protect humans from undesired chemical exposure."

Evangeline Gonzalez, President of the ZeptoMetrix Operation Division, stated, "This investment reinforces our dedication to advancing environmental science. Chiron's state-of-the-art research centre adds a crucial dimension to the ZeptoMetrix portfolio. This means we are even more ready to support our lab and industry partners with critical innovation as they work to address ongoing environmental challenges."

About ZeptoMetrix®

ZeptoMetrix, an Antylia Scientific Company, is the industry leader and manufacturer for innovative solutions solving challenges in the evolving Diagnostic Microbiology Infectious Disease, Oncology market and Analytical Reference Materials for the Applied Markets. We focus on our customers' success by providing premium product quality, reliability, and expert technical knowledge, enabling our customers to develop and advance many applications across diagnostics, pharmaceutical, environmental, food and beverage industries. From in stock solutions to custom control and panel development through to launch, our scientific teams provide our customers with comprehensive, performance-oriented, and cost-effective products and services that positively impact the field of clinical diagnostics, analytical testing and contribute to a healthier world. ZeptoMetrix is an operating division of Antylia Scientific, a holding company of premier life science and diagnostic brands, including Cole-Parmer, Environmental Express and ZeptoMetrix.

Contact Information

Jennifer Button
Deputy Director
jenny.button@chiron.no
+44(0)7963508499

Related Files

Chiron AS Establishes State-of-the-Art Research Centre.pdf

SOURCE: Chiron AS

.

View the original press release on newswire.com.

More from this category

  • Biotechnology
  • 13/12/2024
  • 06:41
ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agenciesSAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that its licensing partners in China, Japan and Australia have filed for approval of neffy® (epinephrine nasal spray) 2 mg in their respective countries. neffy 2 mg was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis,…

  • Biotechnology
  • 13/12/2024
  • 01:11
Cambridge Isotope Laboratories, Inc.

CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers

TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies.OLED display producers rely heavily on deuterated benzene (benzene-d6) as a critical starting material in their synthesis processes. However, this results in significant quantities of depleted benzene-d6, which is no longer usable but still retains considerable deuterium value. The disposal of such depleted material poses environmental challenges and substantial expenses.CIL's benzene-recovery program…

  • Biotechnology, Medical Health Aged Care
  • 11/12/2024
  • 11:58
Jane Morgan Management

NEXSEN Biotech: Revolutionising Global Diagnostics with Nano-Technology Solutions

Sydney, Australia – 11 December, 2024 | NEXSEN Biotech Pty Ltd (“NEXSEN”) is setting a new standard in the diagnostic landscape with its innovative point-of-care (POC) testing solutions. Leveraging state-of-the-art nano-biotechnology, NEXSEN is addressing critical gaps in global healthcare by providing fast, accurate, and affordable diagnostic tools. StrepSure® – Innovative Solutions for Unmet Medical Needs A significant step for maternal and infant health, NEXSEN’s flagship product, StrepSure®, is the world's first rapid diagnostic test for Group B Streptococcus (GBS); a bacterium that is a leading cause for neonatal sepsis, meningitis, and pneumonia, which leads to significant mortality and morbidity in…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.